TRIAL IN PROGRESS: THE FIRST 12-WEEK, RANDOMIZED, CONTROLLED PHASE 2a STUDY OF A THYROID HORMONE RECEPTOR-.ETA AGONIST (TERN-501) ADMINISTERED AS MONOTHERAPY OR IN COMBINATION WITH A FARNESOID X RECEPTOR AGONIST ( TERN--101) IN PATIENTS WITH NASH
HEPATOLOGY（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined